## GMMMG High cost drugs pathway for psoriasis in adults: Outcomes and Monitoring Framework – Version 1 January 2020

| Intervention | Target | Measure | Data source | Who measures | Frequency of reporting – in any financial year |
|---|---|---|---|---|---|
| Quality marker: Patient initiated on biologic therapy if PASI ≥10 and DLQI >10 | 100% of patients should have disease severity score recorded at biologic initiation that reflects treatment as per pathway (this will be via an initiation or switch blueteq form)<br><br>80% of patients should have disease severity score recorded within 4 months of biologic initiation.<br><br>100% of patients at continuation month review should continue therapy only if disease shows an adequate response (defined as either 75% reduction in the PASI score from the start of treatment or a 50% reduction in the PASI score and a 5 point reduction in the DLQI from the start of treatment) | % of patients with disease severity score recorded at biologic initiation or switch<br><br>% of patients with disease severity score recorded within 4 months of biologic initiation<br><br>% of patients at the continuation review who continue therapy only if disease shows an adequate response | Blueteq | SRFT | Annual – end of FY |

| | | | | | |
|---|---|---|---|---|---|
| Quality Marker:<br>Patient continued on biologic therapy by standard disease severity assessment tool | 80% of patients continuing biologic therapy should have a recent (within last 16 months) disease severity score and 95% within 18 months. | % of patients on continuing biologic therapy who have a recent (within last 16 months) disease severity score. | Blueteq | SRFT | Annual – end of FY |
| 5th or 6th line biologic therapy will be subject to MDT approval at a tertiary centre with agreement from ≥ 3 consultants | 100% of patients requiring 5th or 6th line biologic therapy will require approval through MDT at tertiary centre | % of patients requiring 5th or 6th line biologic therapy will require approval through MDT at tertiary centre. 5th and 6th line MDT switch form to be used | Blueteq | SRFT | Annual – end of FY |
| 7th line biologic therapy only to be accessed through IFR | 100% of patients requiring 7th line biologic therapy will require IFR approval | % of patients requiring 7th line biologic therapy will require IFR approval | IFR | GM JCT | Bi-annually |
| Ensure the most cost effective long term biologic is used first line | At least 40% biologic naïve patients to be initiated a best value biologic (currently referenced price adalimumab) | % of initiation prescriptions in biologic naïve patients for each biologic | Blueteq | SRFT | Annual |
| To ensure the best value from medicines – uptake of biosimilar medicines in line with the agreed pathway | All patients considered for biosimilar medication<br><br>All new patients initiated on biosimilar medication where licensed and commercially available<br><br>80% or greater of dispensed doses for infliximab, etanercept, adalimumab are for the biosimilar brand | Exception reporting – number of patients reviewed to switch to biosimilar but remain on originator product<br><br>100% of initiation prescriptions for biosimilar medication where available | Blueteq | SRFT | Quarterly |

| | | | | | |
|---|---|---|---|---|---|
| Measure efficacy of dose escalations | 90% patients on escalated dose will be reviewed in dermatology clinic within 16 months and dose or duration escalation is captured via a continuation form | % of patients on continuing biologic therapy who have a comprehensive annual review which is coordinated by the dermatology service and efficacy of dose or duration escalation is captured | Blueteq | SRFT | Annual |